Resistance mechanisms to genetic suppression of mutant NRAS in melanoma

Melanoma Research
J P RobinsonM W VanBrocklin

Abstract

Targeted therapies have revolutionized cancer care, but the development of resistance remains a challenge in the clinic. To identify rational targets for combination strategies, we used an established melanoma mouse model and selected for resistant tumors following genetic suppression of NRAS expression. Complete tumor regression was observed in all mice, but 40% of tumors recurred. Analysis of resistant tumors showed that the most common mechanism of resistance was overexpression and activation of receptor tyrosine kinases (RTKs). Interestingly, the most commonly overexpressed RTK was Met and inhibition of Met overcame NRAS resistance in this context. Analysis of NRAS mutant human melanoma cells showed enhanced efficacy of cytotoxicity with combined RTK and mitogen-activated protein kinase kinase inhibition. In this study, we establish the importance of adaptive RTK signaling in the escape of NRAS mutant melanoma from inhibition of RAS and provide the rationale for combined blockade of RAS and RTK signaling in this context.

References

Sep 1, 1994·Nature Genetics·C J HussussianN C Dracopoli
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·M G FitzGeraldD A Haber
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F G Haluska, F S Hodi
Aug 24, 2001·The Journal of Biological Chemistry·H RizosR F Kefford
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
May 3, 2003·Cancer Cell·Lance A LiottaEmanuel F Petricoin
Jun 6, 2003·Oncogene·E Sharpless, Lynda Chin
Apr 14, 2004·Journal of Virology·Jennifer L Bromberg-WhiteSheri L Holmen
Sep 17, 2005·Cancer Research·Sheri L Holmen, Bart O Williams
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Neelu PuriRavi Salgia
Aug 5, 2008·Cancer Research·Katherine Stemke-HaleBryan T Hennessy
May 9, 2009·Pigment Cell & Melanoma Research·Matthew W VanbrocklinSheri L Holmen
Jan 14, 2010·Pigment Cell & Melanoma Research·Joseph B MascarenhasDeborah Lang
May 7, 2010·Pigment Cell & Melanoma Research·Matthew W VanBrocklinSheri L Holmen
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Oct 12, 2011·The Journal of Clinical Investigation·Hiromichi EbiJeffrey A Engelman
Oct 22, 2011·Neuro-oncology·Matthew W VanbrocklinSheri L Holmen
Oct 25, 2011·International Journal of Cancer. Journal International Du Cancer·Chandrani ChattopadhyayElizabeth A Grimm
Feb 24, 2012·The New England Journal of Medicine·Jeffrey A SosmanAntoni Ribas
Jul 24, 2012·Cell·Eran HodisLynda Chin
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Apr 2, 2013·The Journal of Clinical Investigation·Ethan V AbelAndrew E Aplin
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen E Sheppard, Grant A McArthur
Jun 21, 2014·Melanoma Research·Inna V FedorenkoKeiran S M Smalley
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertDirk Schadendorf
Jan 12, 2016·Therapeutic Advances in Medical Oncology·Zeynep Eroglu, Antoni Ribas
Mar 19, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ha Linh Vu, Andrew E Aplin
May 11, 2016·The Journal of Investigative Dermatology·Christian PoschSusana Ortiz-Urda

❮ Previous
Next ❯

Citations

Jul 7, 2020·Neoplasia : an International Journal for Oncology Research·Florina GrigoreJames P Robinson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.